Gatifloxacin mesylate is a fourth generation fluoroquinolone antibiotic with broad-spectrum antibacterial activity. It is able to inhibit bacterial type II topoisomerase (IC50 = 13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA rotamase (IC50 = 0.109 μg/ml). It can be used to treat bacterial conjunctivitis in vivo, and its injection can treat acute urinary tract infections with efficacy comparable to levofloxacin hydrochloride injection[1].
